Full-Time

Senior Manager/Associate Director

Commercial Analytics and Business Intelligence

Posted on 10/3/2025

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

No salary listed

New Haven, CT, USA

Hybrid

Must travel to New Haven, CT 3-4x per month.

Category
Data & Analytics (3)
, ,
Required Skills
Python
R
SQL
Word/Pages/Docs
Tableau
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Requires a BA or BS with 5 + years of relevant sales effectiveness, business intelligence, forecasting, targeting and/or insights & analytics experience
  • Pharmaceutical/Biotech or Lifesciences experience required
  • Ability to travel to New Haven, CT 3-4x a month required
  • Pharmaceutical launch experience preferred
  • SQL and/or R programming experience required
  • Experience analyzing and visualizing data from a broad range of commercial data sources (specialty pharmacy dispense/status data, specialty distributor data, patient services data, payer claims/formulary status data, CRM data, etc.)
  • Demonstrated ability to partner with vendors and IT on development of reporting layer within a data warehouse.
  • Demonstrated proficiency in developing complex dashboards in business intelligence tools (e.g. Tableau, PowerBI,)
  • Advanced knowledge & application of MS Office (Excel, PowerPoint, Word, etc.)
  • Excellent oral, written, and presentation skills--able to explain complex concepts clearly to a variety of audiences
  • Must thrive working in a fast-paced, innovative environment while remaining flexible, proactive, resourceful and efficient
  • Excellent interpersonal skills, ability to develop important relationships with key stakeholders, good conflict management and negotiation skills, ability to analyze complex issues to develop relevant and realistic plans and recommendations
  • Must exhibit excellent analytical skills and an ability to communicate complex issues in a simple way
  • Global experience a plus
Responsibilities
  • Control all aspects of performance insights and analytics capabilities including the infrastructure and processes to support all in-line, commercial brand products
  • Develop, maintain, and refine forecasting models
  • Own the targeting process in coordination with Sales, Marketing, Field Operations, and other Commercial functions
  • Claims Data Utilization: Leverage medical and pharmacy claims data sets to generate insights into HCP behavior, market dynamics, payer insights and patient journey
  • Provide Quarterly Business Review framework to assimilate and evaluate brand performance across the commercial organization
  • Owns the process in coordination with Sales, Marketing, Market Access, Field Operations, Patient Services and other functional Heads to identify, recommend, develop and implement strategies, plans and tactics that optimize the success of the company’s commercial products
  • Develops and shares with stakeholders critical business questions, insights and analytics approaches to investigate and provide answers/guidance to support decision making
  • Manages all aspects of building and maintaining standardized and ad hoc KPI dashboards and reports to address executional, operational, and performance related questions for all levels of the Commercial organization and Executive Leadership team
  • Delivers and leads regular performance insights report to senior leadership
  • Collaborates with vendors and the IT team, providing requirements to create the data infrastructure necessary to implement the commercial data strategy and to generate actionable insights and build data models supporting commercial activities
  • Defines how the business can create additional value through the algorithms and utilization of data assets and analytics
  • Manages multiple partners to produce deliverables on strategy within timelines and budget
  • Oversee management of key external vendor relationships
Desired Qualifications

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • DECLARATION Phase 3 trial fully enrolled with mid-2026 data readout for VYD2311 launch.
  • PEMGARDA revenue grew 31% sequentially in Q4 2025, validating antibody prophylaxis market demand.
  • Pipeline expansion into measles, RSV, and long COVID addresses multiple high-need viral indications.

What critics are saying

  • Low COVID community attack rates force 30% trial expansion, risking 6-9 month data delay.
  • Stock price below $1 triggers Nasdaq delisting risk, halting institutional investment and capital access.
  • Competing extended half-life COVID antibodies from AstraZeneca and Regeneron capture immunocompromised market share.

What makes Invivyd unique

  • Proprietary platform combines viral surveillance, predictive modeling, and antibody engineering for evolved immunity.
  • Targets immunocompromised populations underserved by traditional vaccines with monoclonal antibody prophylaxis.
  • FDA Fast Track designation for VYD2311 accelerates COVID-19 prevention development versus competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-5%

2 year growth

-1%
Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

TipRanks
Nov 17th, 2025
Invivyd Announces Common Stock Offering

Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.

Stock Titan
Aug 22nd, 2025
Invivyd Closes $57.5M Public Offering

Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.

INACTIVE